8/7/2008    Enrollment of breast and ovarian cancer patients commenced for combination therapy trial to include Generex Biotechnology’s novel immunotherapeutic vaccine   7/9/2008    Investigational New Drug Application Submitted On Behalf of Generex Biotechnology for Combination Immunotherapy Vaccine Trials   6/26/2008    Generex Biotechnology Expands Mayo Clinic Collaboration for Vaccine Studies   6/23/2008    A Shot in the Arm Against Breast Cancer   6/10/2008    Blood Test for Type-1 Diabetes Coming Soon   6/9/2008    Generex Biotechnology Presented Data At American Diabetes Association Scientific Sessions   6/3/2008    GENEREX BIOTECHNOLOGY PHASE I TRIAL RESULTS FOR NOVEL IMMUNOTHERAPY VACCINE IN BREAST CANCER PATIENTS PRESENTED AT ASCO   3/3/2008    Generex Biotechnology Extends Clinical Trial Agreement for Testing its Synthetic Avian Influenza Vaccine   1/22/2008    GENEREX BIOTECHNOLOGY ANNOUNCES CO-AUTHORSHIP OF PUBLICATIONS WITH JOHNS HOPKINS UNIVERSITY AND STALLERGENES S.A.   12/18/2007    Generex Biotechnology Awarded Patent in Japan   11/5/2007    FIRST PROSTATE CANCER PATIENTS TREATED IN A PHASE I CLINICAL TRIAL AS PART OF A COLLABORATION BETWEEN GENEREX BIOTECHNOLOGY AND THE SAINT SAVAS CANCER HOSPITAL   10/9/2007    Generex Biotechnology RNAi-based Tumor Vaccine Set for Trials in China to be Presented at Leading International Oncology Meeting   8/22/2007    GENEREX BIOTECHNOLOGY TO COLLABORATE WITH LEADING INVESTIGATOR AT ROCHESTER UNIVERSITY ON PANDEMIC AVIAN INFLUENZA VACCINE   8/22/2007    Mass. firm taps UR expert to develop vaccine   7/31/2007    THE INTERNATIONAL JOURNAL OF CANCER PUBLISHES STUDIES ON GENEREX BIOTECHNOLOGY'S ANTI-CANCER ACTIVITY OF ITS IMMUNOTHERAPEUTIC VACCINE   6/14/2007    Generex Biotechnology Awarded New U.S. Patents for Its Core Vaccine Technologies   5/24/2007    Generex Biotechnology Vaccine Strategy Presented at International Conference in London   4/16/2007    GENEREX BIOTECHNOLOGY VACCINE DEVELOPMENT PROGRAMS PRESENTED AT THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH   3/27/2007    Generex Executive Discusses RNAi Platform in Online Interview   3/26/2007    GENEREX BIOTECHNOLOGY TO TEST NOVEL RNAi-BASED IMMUNE-RESPONSE STRATEGY IN CANCER PATIENTS   3/19/2007    GENEREX SCIENTIST TO PRESENT ON THE STATUS OF INFLUENZA VACCINE DEVELOPMENT AT NATIONAL CONFERENCE   2/13/2007    GENEREX BIOTECHNOLOGY EXTENDS SCOPE OF U.S. PATENT PROTECTION FOR VACCINE TECHNOLOGY   2/5/2007    VOLUNTEERS SELECTED FOR HUMAN CLINICAL TRIAL OF GENEREX BIOTECHNOLOGY’S SYNTHETIC AVIAN INFLUENZA VACCINE   2/1/2007    GENEREX BIOTECHNOLOGY TO INITIATE PHASE II CLINICAL TRIALS IN BREAST CANCER PATIENTS IN COLLABORATION WITH UNITED STATES MILITARY’S CANCER INSTITUTE   12/14/2006    Clinical Trial Results from Cancer Vaccine being developed by Generex Biotechnology Subsidiary to be presented at San Antonio Breast Cancer Symposium   11/6/2006    GENEREX BIOTECHNOLOGY TO BEGIN THE FIRST HUMAN CLINICAL TRIAL OF AVIAN INFLUENZA VACCINE   11/2/2006    GENEREX BIOTECHNOLOGY SPONSORS EPISODE OF MEDICAL MISSIONS FOR CHILDREN PLAIN TALK ABOUT HEALTH PROGRAM ON AVIAN INFLUENZA   10/3/2006    GENEREX BIOTECHNOLOGY PUBLISHES STUDIES DEMONSTRATING ANTI-TUMOR POTENTIAL OF IMMUNOTHERAPEUTIC VACCINE   8/8/2006    GENEREX BIOTECHNOLOGY ANNOUNCES EXPANSION OF ANTIGEN EXPRESS CANCER TRIALS TO INCLUDE PROSTATE CANCER PATIENTS   6/8/2006    GENEREX BIOTECHNOLOGY ANNOUNCES PRESENTATION OF INTERIM BREAST CANCER TRIALS RESULTS AND BIRD FLU VACCINE STRATEGY   3/14/2006    Generex Biotechnology to Present Its Avian Influenza Vaccine Program at DNA Forum in London   2/27/2006    Generex Biotechnology to Present Pandemic Influenza Vaccine Program at Bird Flu Summit in Washington, D.C.   2/13/2006    GENEREX BIOTECHNOLOGY COMPLETES POSITIVE PRE-IND MEETING WITH FDA FOR ITS AVIAN FLU VACCINE   1/25/2006    GENEREX BIOTECHNOLOGY ANNOUNCES INTERIM RESULTS OF CLINICAL BREAST CANCER TRIALS   1/23/2006    GENEREX BIOTECHNOLOGY ANNOUNCES FDA PRE-IND MEETING SCHEDULED FOR THE AVIAN FLU VACCINE   11/22/2005    GENEREX BIOTECHNOLOGY AUGMENTS REGULATORY TEAM WITH ENGAGEMENT OF REGULATORY AFFAIRS CONSULTANT   11/17/2005    GENEREX BIOTECHNOLOGY RETAINS RUBENSTEIN PUBLIC RELATIONS   11/17/2005    GENEREX BIOTECHNOLOGY RETAINS WASHINGTON, D.C. – BASED LOBBYIST TO PURSUE OPPORTUNITIES FOR ORAL INSULIN & ITS AVIAN FLU VACCINE   11/9/2005    GENEREX BIOTECHNOLOGY PROPOSES COLLABORATIONS IN CHINA FOR THE CO-DEVELOPMENT OF A NOVEL VACCINE FOR PANDEMIC AVIAN INFLUENZA   11/4/2005    GENEREX SCIENTIST PRESENTS RESULTS OF PANDEMIC INFLUENZA VACCINE PROGRAM AT WASHINGTON CONFERENCE HIGHLIGHTING STRATEGIC ADVANCES IN VACCINES   11/2/2005    GENEREX PANDEMIC INFLUENZA VACCINE PROGRAM TO BE PRESENTED AT NOVEL VACCINE CONCEPTS CONFERENCE IN WASHINGTON DC   10/27/2005    GENEREX BIOTECHNOLOGY PRESENTS PROPOSAL TO INTERESTED U.S. SENATORS TO ACCELERATE DEVELOPMENT OF NOVEL PANDEMIC AVIAN INFLUENZA VACCINE   10/19/2005    GENEREX BIOTECHNOLOGY TO ACCELERATE DEVELOPMENT OF VACCINE FOR PANDEMIC AVIAN INFLUENZA   9/15/2005    GENEREX BIOTECHNOLOGY PRESENTS IMMUNOTHERAPEUTICS STUDY RESULTS AT THE 41ST ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES   9/6/2005    GENEREX BIOTECHNOLOGY RECEIVES AUSTRALIAN PATENT   8/23/2005    MICE WITH HUMAN ANTIGEN PRESENTING MOLECULES DEMONSTRATE STRONG RESPONSES TO NOVEL MELANOMA PEPTIDE VACCINE WHICH IS DESTINED FOR CLINICAL TRIALS   8/16/2005    PANDEMIC INFLUENZA VACCINE DEVELOPMENT ACCELERATED AT GENEREX BIOTECHNOLOGY WITH HIRE OF ACCOMPLISHED SENIOR SCIENTIST   6/22/2005    GENEREX BIOTECHNOLOGY BEGINS RESEARCH COLLABORATION ON NOVEL ALLERGY THERAPY WITH MAJOR EUROPEAN COMPANY   5/11/2005    GENEREX BIOTECHNOLOGY IMMUNE-RESPONSE STRATEGY TO BE TESTED FOR USE AGAINST CANCER   4/28/2005    GENEREX BIOTECHNOLOGY BEGINS TESTING NEW VACCINE FOR BREAST CANCER PATIENTS   4/26/2005    GENEREX BIOTECHNOLOGY RECEIVES AUSTRALIAN PATENT FOR NOVEL VACCINE TECHNOLOGY   4/21/2005    GENEREX BIOTECHNOLOGY COLLABORATOR REPORTS AN ADVANCE IN INTRA-TUMOR GENE THERAPY FOR CANCER   3/22/2005    Generex Biotechnology's Subsidiary Antigen Express Initiates Clinical Trials in Patients with Her-2/neu Positive Breast Cancer   1/27/2005    United States Awards Patent to Antigen Express subsidiary of Generex Biotechnology   11/2/2004    POTENT PRECLINICAL EFFECT OF NOVEL MELANOMA PEPTIDE VACCINE REPORTED AT THE SEVENTH INTERNATIONAL ANTICANCER CONFERENCE IN CORFU, GREECE   10/12/2004    GENEREX BIOTECHNOLOGY PRESENTS INFORMATION AT THE EUROCONFERENCE VACCINES 3 MEETING OF THE PASTEUR INSTITUTE IN PARIS ON THE USE OF NOVEL PEPTIDE VACCINE FOR MELANOMA   10/7/2004    Dr. Eric von Hofe appointed Generex VP for Product Development & Scientific Affairs   9/28/2004    GENEREX BIOTECHNOLOGY ESTABLISHES CRADA WITH THE UNIFORMED SERVICES UNIVERSITY AND THE HENRY M. JACKSON FOUNDATION FOR NOVEL HER-2/NEU VACCINE STUDIES AND CLINICAL TRIALS AT WALTER REED ARMY MEDICAL CENTER IN PATIENTS WITH BREAST CANCER   9/15/2004    GENEREX BIOTECHNOLOGY TESTS NOVEL VACCINE FOR MELANOMA WITH CLINICIAN AT FRED HUTCHINSON CANCER RESEARCH CENTER   8/18/2004    Generex Biotechnology Expands HIV vaccine efforts with leading MGH Investigator   6/22/2004    Generex Biotechnology Presents Potential Uses of RpaidmistR Technology in Transmucosal Vaccines at Merieux Conference in France   6/1/2004    Generex Biotechnology Initiates late Pre-Clinical Studies to Prepare for Vaccine Trials in Patients with Her-2/neu Positive Ovarian Cancer   5/13/2004    GENEREX BIOTECHNOLOGY RECEIVES KEY JAPANESE PATENT FOR NOVEL TECHNOLOGY TO ENHANCE T HELPER CELL RECOGNITION OF CANCER AND BIOTERRORISM ANTIGENS   4/14/2004    INVITED CANCER TREATMENT REVIEW DESCRIBES NOVEL IN SITU CANCER VACCINE TO CURE RECURRENT CANCER   4/6/2004    GENEREX BIOTECHNOLOGY CORPORATION REPORTS SIGNIFICANT ADVANCE IN CANCER   3/3/2004    Generex Biotechnology Working to Develop Diagnostic Kit for Early Detection   2/9/2004    Generex Appoints Dr. Douglas Powell as Director of Immunobiology
	Home | Company | People | Technology | Therapeutic Focus | Business Development | News | Contact © 2004 Antigen Express | Website designed by NRG Networks